Abstract
Neurodegenerative diseases are increasing in prevalence in many countries as the average age of their populations increases, since many of these disorders occur more frequently in elderly individuals, placing an increasing burden on healthcare resources. Most neurodegenerative disorders are associated with accumulations of abnormal proteins in the central nervous system (CNS), which result in neuronal degeneration and ultimately neuronal death. Recent developments in molecular pathology and genetics have allowed the identification of the abnormal proteins involved in many neurodegenerative disorders and the genes that encode these proteins. This has led to a fuller understanding of the mechanisms of many of these diseases, but this has not so far been accompanied by major improvements in diagnostic tests or treatments for these disorders. Prion diseases are rare neurodegenerative disorders that are associated with the accumulation of a misfolded host protein, the prion protein, in the CNS. Prion diseases have been considered as a paradigm for protein misfolding diseases, but there are significant differences between prion diseases and other neurodegenerative disorders, not least in the transmissible nature of prion diseases. In this review we give an overview of the wide range of neurodegenerative diseases that affect humans, and compare the molecular pathology of prion diseases with other neurodegenerative diseases. The concept of proteinopathy as a common mechanism in neurodegenerative disorders is explored, and we highlight the improvements in diagnosis and management required to improve our treatment of these devastating conditions.
Keywords: Neurodegeneration, proteinopathy, prion protein, Aβ protein, α synuclein, plaques, neurofibrillary tangles, tau protein, molecular pathology, central nervous system (CNS).
Current Drug Targets
Title:Molecular Pathology in Neurodegenerative Diseases
Volume: 13 Issue: 12
Author(s): Alexander H. Peden and James W. Ironside
Affiliation:
Keywords: Neurodegeneration, proteinopathy, prion protein, Aβ protein, α synuclein, plaques, neurofibrillary tangles, tau protein, molecular pathology, central nervous system (CNS).
Abstract: Neurodegenerative diseases are increasing in prevalence in many countries as the average age of their populations increases, since many of these disorders occur more frequently in elderly individuals, placing an increasing burden on healthcare resources. Most neurodegenerative disorders are associated with accumulations of abnormal proteins in the central nervous system (CNS), which result in neuronal degeneration and ultimately neuronal death. Recent developments in molecular pathology and genetics have allowed the identification of the abnormal proteins involved in many neurodegenerative disorders and the genes that encode these proteins. This has led to a fuller understanding of the mechanisms of many of these diseases, but this has not so far been accompanied by major improvements in diagnostic tests or treatments for these disorders. Prion diseases are rare neurodegenerative disorders that are associated with the accumulation of a misfolded host protein, the prion protein, in the CNS. Prion diseases have been considered as a paradigm for protein misfolding diseases, but there are significant differences between prion diseases and other neurodegenerative disorders, not least in the transmissible nature of prion diseases. In this review we give an overview of the wide range of neurodegenerative diseases that affect humans, and compare the molecular pathology of prion diseases with other neurodegenerative diseases. The concept of proteinopathy as a common mechanism in neurodegenerative disorders is explored, and we highlight the improvements in diagnosis and management required to improve our treatment of these devastating conditions.
Export Options
About this article
Cite this article as:
H. Peden Alexander and W. Ironside James, Molecular Pathology in Neurodegenerative Diseases, Current Drug Targets 2012; 13 (12) . https://dx.doi.org/10.2174/138945012803530134
DOI https://dx.doi.org/10.2174/138945012803530134 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Neuron Protection as a Therapeutic Target in Acute Ischemic Stroke
Current Topics in Medicinal Chemistry Molecular Profiling - An Essential Technology Enabling Personalized Medicine in Breast Cancer
Current Drug Targets Alzheimer’s Disease – Future Therapy Based on Dendrimers
Current Neuropharmacology The Therapeutic Benefits of Intravenously Administrated Nanoparticles in Stroke and Age-related Neurodegenerative Diseases
Current Pharmaceutical Design Application of Sulfamic Acid in Organic Synthesis-A Short Review
Current Organic Chemistry Pitavastatin and 4-Hydroxy-3-Methoxyacetophenone (HMAP) Reduce Cognitive Dysfunction in Vascular Dementia During Experimental Diabetes
Current Neurovascular Research Cholesterol Oxidation Products and Disease: An Emerging Topic of Interest in Medicinal Chemistry
Current Medicinal Chemistry Effects of Nanosuspension Formulations on Transport, Pharmacokinetics, In Vivo Targeting and Efficacy for Poorly Water-soluble Drugs
Current Pharmaceutical Design FK506 and Its Analogs - Therapeutic Potential for Neurological Disorders
Current Drug Targets - CNS & Neurological Disorders CCL2-CCR2 Signaling in Disease Pathogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets Stem Cells for Microenvironmental Modulation and Retinal Regeneration
Current Tissue Engineering (Discontinued) Direct Targeting of the Ras GTPase Superfamily Through Structure- Based Design
Current Topics in Medicinal Chemistry DLPF Targeted Repetitive Transcranial Magnetic Stimulation Improves Brain Glucose Metabolism Along with the Clinical and Electrophysiological Parameters in CBD Patients
Endocrine, Metabolic & Immune Disorders - Drug Targets Nanoparticle-Based Therapy in Genomics
Current Drug Metabolism A Perspective on Monoamine Oxidase Enzyme as Drug Target: Challenges and Opportunities
Current Drug Targets Melatonin, Autophagy and Intestinal Bowel Disease
Current Pharmaceutical Design Hybrids of Coumarin Derivatives as Potent and Multifunctional Bioactive Agents: A Review
Medicinal Chemistry Oxidative Stress and Antioxidative Enzyme Activities in Chronic Kidney Disease and Different Types of Renal Replacement Therapy
Current Protein & Peptide Science Antitumoral Alkylphospholipids Alter Cell Lipid Metabolism
Anti-Cancer Agents in Medicinal Chemistry From the Editors Perspective: Aquaporins to Apoptosis
Current Neurovascular Research